Through a Distinguished Innovator grant from Novo Foundation to VAR2 Pharma collaborator, University of Copenhagen, the ofCS antibody program has been awarded 1M euro to finalize the preclinical development of the novel cancer targeting antibodies. The grant was partly awarded to promote public private partnerships and entrepreneurship at University of Copenhagen.

.